ArticleTranslational lung cancer research2025
Treatment outcome and safety of durvalumab after concurrent chemoradiation in very elderly patients with unresectable stage III non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Consolidation durvalumab after concurrent chemoradiotherapy (CCRT) has shown a significantly improved progression-free survival (PFS) and overall survival (OS) in patients with unresectable stage III non-small cell lung cancer (NSCLC). However, data on very elderly patients remain limited. This study evaluated the outcomes and safety of durvalumab after CCRT in very elderly patients compared to younger individuals. Methods: We reviewed all unresectable stage III patients with NSCLC treated with durvalumab after CCRT from 2020 to 2024 at four Korean hospitals. Patients were divided into two groups: aged <75 years and ≥75 years. Subgroup analyses using 65- and 70-year cutoffs were also performed. Endpoints included PFS, OS, and adverse events (AEs). Results: Among 46 patients, 13 were aged ≥75 years. The baseline characteristics including performance status and comorbidities were similar. The median PFS was 29 months in patients aged <75 years and 14 months in those aged ≥75 years (P=0.03). The median OS was not reached in patients aged <75 years and was 40 months in those aged ≥75 years (P=0.16). Three-year OS was 75.2% in patients aged <75 years and 57.7% in those aged ≥75 years (P=0.16). AEs rates were comparable between groups. Conclusions: In patients aged ≥75 years with unresectable stage III NSCLC, durvalumab after CCRT was associated with shorter PFS and comparable AE profiles to younger patients. OS appeared similar, but the small sample size limits interpretation. Comprehensive geriatric assessment may help guide treatment decisions before initiating durvalumab after CCRT in very elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.